Hypofractionated Radiotherapy

Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)

Hypofractionated Radiotherapy +Chemotherapy+ Camrelizumab as Neoadjuvant Therapy for Pancreatic Cancer

Hypofractionated Radiotherapy for Soft Tissue Sarcomas

Hypofractionated vs Conventional RT After Prosthetic Breast Reconstruction

A Phase II Study of Pirfenidone Plus PD-1 Inhibitor With or Without Hypofractionated Radiotherapy for Refractory pMMR/MSS Colorectal Cancer

Hypofractionated Whole Pelvic Chemoradiotherapy With iRex Optimization in Cervical Cancer

Postoperative Hypofractionated Whole Pelvic Radiotherapy in Cervical and Endometrial Cancer

Hypofractionated Radiotherapy for Postoperative Intermediate-Risk Head and Neck Squamous Cell Carcinoma

Hypofractionated Radiation Therapy vs Standard Treatment in Breast Cancer.

Faecal Incontinence in Prostate Cancer Survivors Treated Whith Radiotherapy

BreastVAX: Radiation Boost to Enhance Immune Checkpoint Blockade Therapy

Iparomlimab and Tuvonralimab Plus Hypofractionated Radiotherapy and Chemotherapy for HAHNSCC

Cetuximab β Combined With PRaG Regimen in the Treatment of EGFR-positive Advanced Refractory Solid Tumors

Hypofractionated Radiotherapy Plus Immunochemotherapy for Neoadjuvant Treatment of Gastroesophageal Junction Adenocarcinoma

Hypofractionated Radiotherapy Combined With Immunochemotherapy for Conversion Treatment of Gastroesophageal Junction Adenocarcinoma

Radiation Therapy Followed by Tislelizumab and Anlotinib Aeoadjuvant/Adjuvant Therapy for Stage II-IIIA NSCLC

Conventional Versus Hypofractionated Radiotherapy With Temozolomide in Elderly Glioblastoma

Radiotherapy With Hyperthermia in Recurrent and Radiation-Induced Sarcomas

A Study of Erlotinib Plus Radiotherapy (RT) for Patients With Advanced or Inoperable Non-Small-Cell Lung Cancer

Hypofractionated Radiotherapy Plus Immunotherapy Versus Conventional Radiotherapy in Locally Recurrent Rectal Cancer